Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MicroRNA profiling of paediatric AML with FLT-ITD or MLL-rearrangements: Expression signatures and in vitro modulation of miR-221-3p and miR-222-3p with BRD4/HATs inhibitors.
Leoncini PP, Vitullo P, Reddel S, Tocco V, Paganelli V, Stocchi F, Mariggiò E, Massa M, Nigita G, Veneziano D, Fadda P, Scarpa M, Pigazzi M, Bertaina A, Rota R, Pagliara D, Merli P. Leoncini PP, et al. Among authors: mariggio e. Oncol Rep. 2022 Dec;48(6):221. doi: 10.3892/or.2022.8436. Epub 2022 Nov 2. Oncol Rep. 2022. PMID: 36321792 Free PMC article.
Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.
Vinti L, Pagliara D, Buffardi S, Di Ruscio V, Stocchi F, Mariggiò E, Parasole R, Di Matteo A, Petruzziello F, Paganelli V, De Vito R, Del Bufalo F, Strocchio L, Locatelli F. Vinti L, et al. Among authors: mariggio e. Pediatr Blood Cancer. 2022 Apr;69(4):e29557. doi: 10.1002/pbc.29557. Epub 2022 Feb 2. Pediatr Blood Cancer. 2022. PMID: 35107876
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Latagliata R, Attolico I, Trawinska MM, Capodanno I, Annunziata M, Elena C, Luciano L, Crugnola M, Bergamaschi M, Bonifacio M, Baratè C, Mauro E, Binotto G, Sgherza N, Aguzzi C, Monteleone B, Sorà F, Caocci G, Luzi D, Mariggiò E, Scaffidi L, Cattaneo D, Gozzini A, Di Veroli A, Abruzzese E, Galimberti S, Iurlo A, Specchia G, Breccia M. Latagliata R, et al. Among authors: mariggio e. Hematol Oncol. 2021 Aug;39(3):401-408. doi: 10.1002/hon.2851. Epub 2021 Mar 13. Hematol Oncol. 2021. PMID: 33617659
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort.
Chiatamone Ranieri S, Arleo MA, Trasarti S, Bizzoni L, Carmosino I, De Luca ML, Mohamed S, Mariggiò E, Scalzulli E, Rosati S, De Benedittis D, Colafigli G, Pepe S, Molica M, Scamuffa MC, Di Prima A, Ferretti A, Baldacci E, Mancini M, Santoro C, Vignetti M, Breccia M, Latagliata R. Chiatamone Ranieri S, et al. Among authors: mariggio e. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e328-e333. doi: 10.1016/j.clml.2020.11.003. Epub 2020 Nov 6. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33342728
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance.
Mohamed S, Latagliata R, Limongi MZ, Nigro S, Sangiorgi E, Nanni M, Piccioni A, Campagna A, Spiriti MAA, Carmosino I, Molica M, Mariggiò E, Rosati S, Colafigli G, Fazio F, Luca ML, Benedittis D, Scalzulli E, Breccia M, Mancini M. Mohamed S, et al. Among authors: mariggio e. Leuk Lymphoma. 2020 Dec;61(14):3476-3483. doi: 10.1080/10428194.2020.1811861. Epub 2020 Sep 1. Leuk Lymphoma. 2020. PMID: 32870062
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
Cesini L, Carmosino I, Breccia M, De Benedittis D, Mohamed S, De Luca ML, Colafigli G, Molica M, Scalzulli E, Massaro F, Mariggiò E, Rizzo L, Loglisci MG, Scamuffa MC, Vozella F, Diverio D, Mancini M, Alimena G, Foà R, Latagliata R. Cesini L, et al. Among authors: mariggio e. Oncol Res Treat. 2019;42(12):660-664. doi: 10.1159/000502801. Epub 2019 Oct 8. Oncol Res Treat. 2019. PMID: 31593970
MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
Zingoni A, Vulpis E, Cecere F, Amendola MG, Fuerst D, Saribekyan T, Achour A, Sandalova T, Nardone I, Peri A, Soriani A, Fionda C, Mariggiò E, Petrucci MT, Ricciardi MR, Mytilineos J, Cippitelli M, Cerboni C, Santoni A. Zingoni A, et al. Among authors: mariggio e. Front Immunol. 2018 May 1;9:926. doi: 10.3389/fimmu.2018.00926. eCollection 2018. Front Immunol. 2018. PMID: 29765374 Free PMC article.